Lixte Biotechnology
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2004-01-01
- Employees
- 4
- Market Cap
- -
- Website
- http://www.lixte.com
- Introduction
Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing a drug class called protein phosphatase 2A inhibitors. The firm is also involved in utilizing biomarker technology to identify enzyme targets associated with serious common diseases and then designing novel compounds to attack those targets. The company was founded by John S. Kovach and Robert B. Royds on May 24, 2005 and is headquartered in Pasadena, CA.
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- First Posted Date
- 2019-03-22
- Last Posted Date
- 2019-04-08
- Lead Sponsor
- Lixte Biotechnology Holdings, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT03886662
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Phase I Study of LB-100 With Docetaxel in Solid Tumors
Phase 1
Completed
- Conditions
- NeoplasmsTumorsCancer
- Interventions
- First Posted Date
- 2013-04-23
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Lixte Biotechnology Holdings, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT01837667
- Locations
- 🇺🇸
Texas Oncology - Tyler, Tyler, Texas, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
© Copyright 2025. All Rights Reserved by MedPath